Indaptus Therapeutics, Inc. announced data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company's Decoy anti-tumor platform. The poster, titled, A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy, authored by Michael J. Newman, Ph.D., the Company's Founder and Chief Scientific Officer, was presented April 18, 2023. Highlights included: Decoy10 (a previous generation from the platform) is a novel, attenuated and stabilized multi-TLR, NLR and STING agonist bacteria-based immunotherapy that demonstrated 90% reduction of LPS-endotoxin activity and use of 100% killed, non-pathogenic bacteria.

Decoy10 inhibited tumor growth, metastasis, and induced tumor regressions as a single agent. Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody. Regressions were durable and associated with immunological memory-mediated rejection of tumor rechallenge.

The data demonstrated that Decoy10 contains agonists of TLR2 (1/2 and 2/6), TLR4, TLR8, TLR9, NOD2 and STING, conferring the ability to activate both innate and adaptive immune pathways in tumors after a single safe i.v. dose of Decoy10 in combination with anti-PD-1 checkpoint therapy, an NSAID or both. In vivo anti-tumor activity was seen with colorectal, breast, hepatocellular, pancreatic carcinomas, and non-Hodgkin's lymphomas (mouse and human) in pre-clinical models.